Melissa.Moore

CSO, Moderna Therapeutics, RNA expert

[NowThis Impact @nowthisimpact]

This chief scientific officer at Moderna breaks down the misunderstandings about the mRNA in the COVID-19 vaccine, and explains how it could change the world

(via @TEDTalks)

[Alltrna @alltrna]

Today we welcome world leaders in #RNA research and therapeutics to our SAB. We will work with them to harness the power of #tRNA biology to advance a single medicine with the potential to treat thousands of diseases.

Release: https://t.co/rd2XfXMGMD
https://t.co/kMConnQy7w

[Melissa.Moore @mooreorless62]

I’m very excited to be part of this new company!

[Alltrna @alltrna]

We are Alltrna, the world’s first #tRNA platform company. We are harnessing the power of #tRNAbiology to create a new class of #programmablemedicines with the potential to treat thousands of diseases.

https://t.co/GlrfN3gy0H

@FlagshipPioneer #tRNAtherapeutics #machinelearning

[Nasdaq Exchange @NasdaqExchange]

The pace of progress in medicine is moving at record speed. Discover how Nasdaq-100 listed Moderna is accelerating innovation to meet unmet medical needs.

[Moderna @moderna_tx]

We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study.
Read more: https://t.co/vYWEy8CKCv

[Moderna @moderna_tx]

We just announced a longer shelf life at refrigerated temperatures for mRNA-1273, our COVID-19 vaccine candidate. Read more: https://t.co/4ymyQ2NS1N

[International mRNA Health Conference @mrnaconference]

Announcing the exciting PROGRAM of the 8th International #mRNA Health Conference​! Comprehensive topics will be presented including a special focus on #COVID19 #vaccines!

https://t.co/eYv1qfa6yk

[Melissa.Moore @mooreorless62]

Forward-Looking Information and Factors That May Affect Future Results https://t.co/JLySyOpLJs

[Melissa.Moore @mooreorless62]

@jmcoller @JHU_BDPs @JohnsHopkins Congrats!

[Melissa.Moore @mooreorless62]

Congratulations @Alnylam! A great day for the entire RNA therapeutics community!

[John Maraganore 🇺🇸🇬🇷🇺🇦 @JMaraganore]

Today’s @US_FDA approval of GIVLAARI is a defining moment for @Alnylam as we become a multi-product commercial company, for the field of #RNAi with the 1st ever approved GalNAc-conjugate RNAi tx & most importantly, for #raredisease patients awaiting a new treatment option.

[Melissa.Moore @mooreorless62]

Happy Mole Day everyone! https://t.co/dLHvo0tEZK

[Melissa.Moore @mooreorless62]

Thank you IUBMB!

[IUBMB @iubmb]

Congratulations to Melissa Moore, Moderna Therapeutics @moderna_tx, for being named IUBMB Jubilee Lecturer at the RNA Society 2020 meeting in beautiful Vancouver, Canada. This award recognizes her outstanding contributions to RNA biology and therapeutics. @RNASociety @CSMB_SCBM

[Melissa.Moore @mooreorless62]

The perfect piece of #Modernart for #RNADay ⁦@moderna_tx⁩! Long live our polysome!

[Melissa.Moore @mooreorless62]

The perfect wine for a spliceosome enthusiast on #RNADay! Thanks @sainiharleen! Or should I say Dr. Saini?

[Melissa.Moore @mooreorless62]

https://t.co/aAZx9JGC1y

[Melissa.Moore @mooreorless62]

Hurricane Maria's Death Toll Was Decades In The Making https://t.co/rLS7PVbSD6

[BusinessWire-Science @BW_Science]

Moderna Announces an Array of Clinical Advances and Outlines 2018 Priorities; 19 Development Candidates, including 10 Clinical Programs, Highlight Productivity of mRNA Platform https://t.co/TcoZhQjjwg

[Bertrand Delsuc @BertrandBio]

Moderna #JPM18 450m$ invested in R&D in 2017...
pipeline below: 19 candidates, 10 clinical trials

[Madeleine Armstrong @ByMadeleineA]

Moderna to start phase II trial of @AstraZeneca-partnered VEGF project “in matter of weeks”, says Stephane Bancel #JPM18